AC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
Lausanne, Switzerland, January 22, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will regain all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab following termination of the collaboration agreements with Genentech, a member of the Roche Group, and Roche. Both antibodies have been evaluated in clinical studies for Alzheimer’s disease (AD). AC Immune will also regain rights to existing GMP drug-product for clinical testing as well as associated data generated under each of the agreements. AC Immune will carefully review and evaluate available data sets, including the final open label extension results from the Lauriet trial when they become available and are received in full by AC Immune, before decisions are made on potential further development and other opportunities.
Related news for (ACIU)
- AC Immune and Takeda Sign Exclusive Option and License Agreement Valued up to $2.1B
- AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases
- AC Immune Announces Pricing of Underwritten Offering of Common Shares
- AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease